Using AI & ML For Vaccine Development, Startup Deepflare Nets €1.5M

July 26, 2022 | 2 minutes read

Poland-based startup that uses AI and ML models for mRNA vaccine development has gathered funding of €1.5 million.

Deepflare, a Polish startup that utilizes Machine Learning (ML) and Artificial Intelligence (AI) to  expedite mRNA vaccine development has received funding of €1.5 million. In an equity round led by German fund Sunfish Partners, including Estonian VC Lemonade Stand and angel investors Przemek Kowalczyk,  Szymon Sypniewicz-co-founders Ramp. The R&D grants were given by the Polish Development Fund and Poland’s  National Centre for Research and Development

AI in recent years has emerged as a powerhouse in the healthcare sector. As per stats, the use of AI in healthcare will surpass  $34 billion by 2025. It has provided multiple benefits such as early detection of diseases, improved patient management and better communication etc. And recently after the pandemic many startups have also emerged, steering the attention of investors-such as Endimension which grabbed funding of $300,000.

However,  Deepflare has a mission to accelerate vaccine discovery by employing AI. According to the startup,  their technology and Machine Learning models accelerate the drug development process and increase vaccine efficiency against the current and future variants of the viruses. The mission of the company is to fully unlock the potential of mRNA by optimizing the drug development pipeline and automating the whole process of finding vaccine candidates.

Founded in 2020 by  Piotr Grzegorczyk, Stanisław Gizińsk and Grzegorz Preibisch in Warsaw with the goal to analyze genomes of SARS-CoV-2. The platform has developed AI technology that also predicts future variants and quickly finds sequences to contain drugs and vaccine. Now the company is using its technology and AI prediction models to boost development of mRNA vaccines and drugs against other viral diseases.

This funding can be quite beneficial as the startup aims to use this pre-seed funding to further enhance its technology and expand its ML model outside of Poland, primarily in the EU, UK and US.